Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | FABP3 | P05413 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL577110 | 0.86 | PTGS2 (0.50) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL577295 | 0.81 | PTGS2 (0.53) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL3884087 | 0.79 | PTGS2 (0.68) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL5533958 | 0.78 | PTGS2 (0.82) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL26193724 | 0.77 | PTGS2 (0.62) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL5534966 | 0.76 | PTGS2 (0.79) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL27595572 | 0.76 | PTGS2 (0.64) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| Lumiracoxib SCHEMBL29377334 | 0.76 | PTGS2 (1.00) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| Lumiracoxib SCHEMBL4479 | 0.76 | PTGS2 (1.00) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| Lumiracoxib SCHEMBL29475008 | 0.76 | PTGS2 (1.00) | PTGS2PTGS1ABCB11PPARGNR1I3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100516037-C | Nitrooxyderivatives of cyclooxygenase-2 inhibitors | NICOX SA (FR) | 2009-07-22 | — | — | CN | disclosed |
| EP-1684784-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A NEUROTROPHIC FACTOR-MODULATING AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM MEDIATED DISORDERS | Pharmacia & Upjohn Company LLC (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1670417-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR ADMINISTERED UNDER HYPOTHERMIC CONDITIONS FOR THE TREATMENT OF ISCHENIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | Pharmacia Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| CN-1662490-A | Nitrooxyderivatives of cyclooxygenase-2 inhibitors | NICOX SA (FR) | 2005-08-31 | — | — | CN | disclosed |
| WO-2005046615-A2 | COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM MEDIATED DISORDERS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005037193-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR ADMINISTERED UNDER HYPOTHERMIC CONDITIONS FOR THE TREATMENT OF ISCHEMIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |